Press Releases

23 June 2023
Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
2 June 2023
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
26 May 2023
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission
25 May 2023
Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023
8 May 2023
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
24 April 2023
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
3 April 2023
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
28 March 2023
BioNTech Announces New ADS Repurchase Program
27 March 2023
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
20 March 2023
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.